Literature DB >> 23197598

Making medicines evergreen.

Andrew W Hitchings1, Emma H Baker, Teck K Khong.   

Abstract

Mesh：

Substances：

Year:  2012        PMID： 23197598     DOI： 10.1136/bmj.e7941

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  8 in total

1.  Approvals and Timing of New Formulations of Novel Drugs Approved by the US Food and Drug Administration Between 1995 and 2010 and Followed Through 2021.

Authors:  Ravi Gupta; Christopher J Morten; Angela Y Zhu; Reshma Ramachandran; Nilay D Shah; Joseph S Ross
Journal:  JAMA Health Forum       Date:  2022-05-20

2.  Approval policies for modifications to machine learning-based software as a medical device: A study of bio-creep.

Authors:  Jean Feng; Scott Emerson; Noah Simon
Journal:  Biometrics       Date:  2020-10-11       Impact factor: 2.571

3.  Releasing GP capacity with pharmacy prescribing support and New Ways of Working: a prospective observational cohort study.

Authors:  Margaret Maskrey; Chris F Johnson; Jason Cormack; Margaret Ryan; Hector Macdonald
Journal:  Br J Gen Pract       Date:  2018-10       Impact factor: 5.386

4.  Is Patent "Evergreening" Restricting Access to Medicine/Device Combination Products?

Authors:  Reed F Beall; Jason W Nickerson; Warren A Kaplan; Amir Attaran
Journal:  PLoS One       Date:  2016-02-24       Impact factor: 3.240

5.  Patented drug extension strategies on healthcare spending: a cost-evaluation analysis.

Authors:  Nathalie Vernaz; Guy Haller; François Girardin; Benedikt Huttner; Christophe Combescure; Pierre Dayer; Daniel Muscionico; Jean-Luc Salomon; Pascal Bonnabry
Journal:  PLoS Med       Date:  2013-06-04       Impact factor: 11.069

6.  Does educational intervention improve doctors' knowledge and perceptions of generic medicines and their generic prescribing rate? A study from Malaysia.

Authors:  Mohamed Azmi Hassali; Zhi Yen Wong; Alian A Alrasheedy; Fahad Saleem; Abdul Haniff Mohamad Yahaya; Hisham Aljadhey
Journal:  SAGE Open Med       Date:  2014-11-05

7.  Lost cost savings to the NHS in England due to the delayed entry of multiple generic low-dose transdermal buprenorphine: a case scenario analysis.

Authors:  Stephen Robert Chapman; Mohammed Ibrahim Aladul; Raymond William Fitzpatrick
Journal:  BMJ Open       Date:  2019-08-01       Impact factor: 2.692

8.  Improving the odds of drug development success through human genomics: modelling study.

Authors:  Aroon D Hingorani; Valerie Kuan; Chris Finan; Felix A Kruger; Anna Gaulton; Sandesh Chopade; Reecha Sofat; Raymond J MacAllister; John P Overington; Harry Hemingway; Spiros Denaxas; David Prieto; Juan Pablo Casas
Journal:  Sci Rep       Date:  2019-12-11       Impact factor: 4.379
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.